| 马新欣,权乾坤,田 苑,张 欢,郭丽阳.帕罗西汀治疗阿尔兹海默症合并抑郁对血清NE以及5-HT表达的影响[J].现代生物医学进展英文版,2020,(21):4080-4083. |
| 帕罗西汀治疗阿尔兹海默症合并抑郁对血清NE以及5-HT表达的影响 |
| Effects of Paroxetine on Alzheimer's Disease Combined with Depression on Serum NE and 5-HT Expression |
| Received:February 28, 2020 Revised:March 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.21.017 |
| 中文关键词: 帕罗西汀 阿尔兹海默症 抑郁 去甲肾上腺素 5-羟色胺 |
| 英文关键词: Paroxetine Alzheimer's disease Depression Norepinephrine 5-hydroxytryptamine |
| 基金项目:陕西省自然科学基金项目（2017JQ8039） |
|
| Hits: 859 |
| Download times: 590 |
| 中文摘要: |
| 摘要 目的：探讨帕罗西汀治疗阿尔兹海默症合并抑郁对血清去甲肾上腺素(Noradrenaline，NE)以及5-羟色胺(5-hydroxytryptamine，5-HT)表达的影响。方法：2017年9月到2019年8月选择在本院诊治的98例阿兹尔海默症合并抑郁患者，根据治疗方法的不同分为帕罗西汀组50例与多奈哌齐组48例。多奈哌齐组给予多奈哌齐治疗，帕罗西汀组在多奈哌齐组治疗的基础上给予帕罗西汀治疗，两组治疗观察3个月，记录血清NE、5-HT表达变化情况。结果：帕罗西汀组的总有效率是96.0 % (48/50)，显著高于多奈哌齐组的79.2 % (38/48) (P<0.05)。两组治疗前的MMSE评分对差异比无统计学意义(P<0.05)，两组治疗后的MMSE评分显著高于治疗前(P<0.05)，且帕罗西汀组也显著高于多奈哌齐组(P<0.05)。帕罗西汀组治疗期间的便秘、嗜睡、头晕、心动过速、肝功能异常等不良反应发生率为40.0 % (20/50)，多奈哌齐组为31.3 % (15/48)，两组对比差异无统计学意义(P>0.05)。两组治疗前血清NE、5-HT含量对比差异无统计学意义(P>0.05)；两组治疗后的血清NE、5-HT含量显著高于治疗前(P<0.05)，且帕罗西汀组也显著高于多奈哌齐组(P<0.05)。结论：帕罗西汀治疗阿尔兹海默症合并抑郁能促进血清NE、5-HT的释放，改善患者的认知功能，提高治疗效果确切，且不会增加不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of paroxetine in the treatment of Alzheimer's disease combined with depression on serum noradrenaline (NE) and 5-hydroxytryptamine (5-HT) expression. Methods: From September 2017 to August 2019, 98 cases of patients with Alzheimer's disease and depression who were selected for treatment in our hospital were selected and divided into 50 cases of paroxetine group and 48 cases of donepezil group accorded to different treatment methods. The donepezil group were treated with donepezil, and the paroxetine group were given paroxetine on the basis of the donepezil group. The two groups were observed for 3 months, and the changes in serum NE and 5-HT expression were recorded. Results: The total effective rates of the paroxetine group were 96.0 % (48/50), which were significantly higher than 79.2 % (38/48) of the donepezil group (P<0.05). There was no significant difference in the MMSE score pretherapy between the two groups (P<0.05). The MMSE scores of the two groups post-treatment was significantly higher than pretherapy (P<0.05), and the paroxetine group was also significantly higher than that of the donepezil group (P<0.05). The incidences of adverse reactions such as constipation, drowsiness, dizziness, tachycardia, and abnormal liver function during the treatment of paroxetine in the paroxetine group were 40.0 % (20/50), so that were 31.3 % (15/48) in the donepezil group, compared were no statistically significant difference (P>0.05). There was no statistically significant difference in serum NE and 5-HT levels between the two groups pretherapy (P>0.05). The levels of serum NE and 5-HT in the two groups post-treatment were significantly higher than pretherapy (P<0.05), and the paroxetine group were significantly higher than that in the donepezil group (P<0.05). Conclusion: Paroxetine in the treatment of Alzheimer's disease combined with depression can promote the release of serum NE and 5-HT, improve the cognitive function of patients, and improve the treatment effect without increasing the incidence of adverse reactions. |
|
View Full Text
View/Add Comment Download reader |
| Close |
